- Home
- LSAK vs IMAB Comparison
LSAK vs IMAB Comparison
Compare LSAK & IMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LSAK
- IMAB
- Stock Information
- Founded
- LSAK 1997
- IMAB 2014
- Country
- LSAK South Africa
- IMAB United States
- Employees
- LSAK N/A
- IMAB N/A
- Industry
- LSAK Investment Bankers/Brokers/Service
- IMAB Biotechnology: Pharmaceutical Preparations
- Sector
- LSAK Finance
- IMAB Health Care
- Exchange
- LSAK Nasdaq
- IMAB Nasdaq
- Market Cap
- LSAK 344.5M
- IMAB 384.6M
- IPO Year
- LSAK N/A
- IMAB 2020
- Fundamental
- Price
- LSAK $4.61
- IMAB $4.38
- Analyst Decision
- LSAK
- IMAB Strong Buy
- Analyst Count
- LSAK 0
- IMAB 4
- Target Price
- LSAK N/A
- IMAB $6.75
- AVG Volume (30 Days)
- LSAK 17.0K
- IMAB 2.1M
- Earning Date
- LSAK 11-05-2025
- IMAB 11-02-2025
- Dividend Yield
- LSAK N/A
- IMAB N/A
- EPS Growth
- LSAK N/A
- IMAB N/A
- EPS
- LSAK N/A
- IMAB N/A
- Revenue
- LSAK $574,080,000.00
- IMAB N/A
- Revenue This Year
- LSAK $1.06
- IMAB N/A
- Revenue Next Year
- LSAK $13.32
- IMAB N/A
- P/E Ratio
- LSAK N/A
- IMAB N/A
- Revenue Growth
- LSAK 4.13
- IMAB N/A
- 52 Week Low
- LSAK $3.39
- IMAB $0.60
- 52 Week High
- LSAK $5.60
- IMAB $5.90
- Technical
- Relative Strength Index (RSI)
- LSAK 47.41
- IMAB 54.65
- Support Level
- LSAK $4.50
- IMAB $4.17
- Resistance Level
- LSAK $4.76
- IMAB $4.69
- Average True Range (ATR)
- LSAK 0.13
- IMAB 0.53
- MACD
- LSAK -0.02
- IMAB -0.12
- Stochastic Oscillator
- LSAK 24.49
- IMAB 25.44
About LSAK Lesaka Technologies Inc.
Lesaka Technologies Inc provides payment solutions, transaction processing solutions, and financial technologies. The company operates two reportable segments: Merchant and Consumer. The company operates mainly within South Africa. The Merchant segment that derives majority revenue includes activities related to the provision of goods and services provided to corporate and other juristic entities. It earns fees from processing activities performed for its customers and revenue generated from the distribution of prepaid airtime. The Consumer segment includes activities related to the provision of financial services to customers, including bank accounts, loans, and insurance products. The firm charges monthly administration fees for all bank accounts.
About IMAB I-MAB
I-MAB is a clinical-stage biotech company. Along with its subsidiaries, it is principally engaged in discovering and developing transformational biologics in the fields of immuno-oncology and immuno-inflammation diseases in the People's Republic of China and other countries and regions. Its drug pipeline includes Uliledlimab (TJD5) which is an antibody for solid tumors, Ragistomig (TJ-L14B), and Givastomig (TJ-CD4B).